Cargando…
ABX464: a good drug candidate instead of a magic bullet
Despite the significant number of antiviral drugs that are currently available in the clinics of developed countries, none of these affect the production stage of HIV-1 replication, more specifically the process of viral gene expression. For instance, several early attempts failed to generate inhibi...
Autores principales: | Berkhout, Ben, van der Velden, Yme U |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515925/ https://www.ncbi.nlm.nih.gov/pubmed/26215448 http://dx.doi.org/10.1186/s12977-015-0189-x |
Ejemplares similares
-
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing
por: Vautrin, Audrey, et al.
Publicado: (2019) -
The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages
por: Chebli, Karim, et al.
Publicado: (2017) -
RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation
por: Manchon, Laurent, et al.
Publicado: (2017) -
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases
por: Apolit, Cécile, et al.
Publicado: (2022) -
Pre-referral rectal artesunate is no “magic bullet” in weak health systems
por: Hetzel, Manuel W., et al.
Publicado: (2023)